Company overview

Breathtaking science

At Verona Pharma our vision is to become a leader in developing and commercializing innovative treatments to improve the health and quality of life of the millions of people affected by chronic respiratory diseases.
 

Overview

Verona Pharma plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs.

Our proprietary lead candidate, RPL554, is paving the way for a new generation of drugs, with a novel mode of action, and has the potential to provide relief for the many patients suffering from respiratory conditions such as chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and possibly asthma.

RPL554 is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4), that act as both a bronchodilator and an anti-inflammatory agent in a single compound. There is no therapy currently available that acts as both a bronchodilator and anti-inflammatory in a single compound for the treatment of respiratory diseases. We believe RPL554 has the potential to be the first novel type of bronchodilator in over forty years.

Verona Pharma is listed on the NASDAQ Global Market and the London Stock Exchange and is supported by a number of large, specialist healthcare focused investors from the US, UK and Europe.

 

This is an example photo
We believe RPL554 has the potential to be the first novel type of bronchodilator in over forty years

Our team

We have established a management team and Board of Directors with extensive experience in large pharmaceutical and biotechnology companies in respiratory product development from drug discovery through commercialization and have played important roles in the development and commercialization of several approved respiratory treatments. They are supported by clinical and scientific advisors with industry and academic experience.

 

Strategy and business model

Our strategy

Our vision is to become a leader in developing innovative treatments for respiratory diseases with significant unmet medical needs. Our current focus is on RPL554, which we believe has the potential to become an important and novel treatment and standard of care for chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) and other respiratory diseases, including asthma.

The key elements of our strategy and clinical development program to achieve this vision include:

  • Rapidly advance the development of nebulized RPL554 for the treatment of COPD. We intend to develop RPL554 as a maintenance treatment of COPD and as a treatment for acute exacerbations of COPD. We are developing RPL554 both as a single agent and as an add-on therapy with standard-of-care bronchodilators.
     
  • Develop RPL554 for the treatment of CF. We intend to develop RPL554 for the treatment of cystic fibrosis. CF is considered an orphan disease by both the FDA and EMA.
     
  • Develop a DPI and MDI formulation of RPL554 for the treatment of COPD and asthma. In addition to nebulized RPL554, we are developing DPI and MDI formulations of RPL554 for the treatment of COPD patients. We believe the development of DPI and MDI formulations has the potential to significantly increase the market opportunity for RPL554 as a maintenance treatment for COPD. We may also pursue development of RPL554 in these formulations for the treatment of asthma.
     
  • Pursue development of RPL554 in other forms of respiratory disease. We believe that RPL554’s properties as an inhaled, dual inhibitor of PDE3 and PDE4 give it broad potential applicability in the treatment of other respiratory diseases, including asthma. We may pursue these development activities either by ourselves or with collaborators.
     
  • Seek strategic collaborative relationships. We may seek strategic collaborations with market-leading biopharmaceutical companies to develop and commercialize RPL554. We believe these collaborations could provide significant funding to advance the development of RPL554 while allowing us to benefit from the development and commercialization expertise of our collaborators.
     
  • Acquire or in-license product candidates for the treatment of respiratory diseases. We plan to leverage our respiratory disease expertise to identify and in-license or acquire additional clinical-stage product candidates that we believe have the potential to become novel treatments for respiratory diseases with significant unmet medical needs.

 

Click here for further information on RPL554.

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us